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Background: Although heavy drinking is known to lead to liver injury, some recent studies have reported that light
alcohol consumption (LAC) may play a protective role against fatty liver in the general population, and may even
play a protective role against non-alcoholic fatty liver disease (NAFLD) in males with metabolic syndrome (MS).
However, the association between LAC and fatty liver with liver enzyme elevation in females with MS is unclear.
Methods: Participants of this study were 20,853 females who underwent a regular health check-up between April
2008 and March 2012 at our hospital. Enrolled subjects were 1141 females with MS, who underwent all necessary
tests and drank less than 20 g/day of alcohol. We investigated the presence of fatty liver with liver enzyme elevation,
defined in this study as alanine aminotransferase (ALT) levels≧31 IU/I, and the association between LAC and fatty liver
with ALT elevation.
Results: There was no significant difference in the prevalence of fatty liver and ALT between light drinkers and
non-drinkers. The prevalence of individuals receiving a treatment for dyslipidemia and impaired glucose tolerance
(IGT) was significantly lower in light drinkers than in non-drinkers. Body mass index (BMI), waist circumference (WC),
diastolic blood pressure (DBP), triglyceride (TG), uric acid (UA), IGT, and visceral fat type MS (V-type MS) were significant
predictors of the prevalence of fatty liver with ALT elevation in logistic regression analysis. The odds ratio [OR] (95 %
confidence interval [CI], p value) for fatty liver with ALT elevation were as follows: BMI, 2.181 (1.445–3.293, p <0.001); WC,
1.853 (1.280–2.684, p <0.01); DBP, 1.604 (1.120–2.298, p <0.05); TG, 2.202 (1.562–3.105, p <0.001); UA, 2.959 (1.537–5.698,
p <0.01); IGT, 1.692 (1.143–2.506, p <0.01); and V-type MS, 3.708 (2.529–5.437, p <0.001).
Conclusions: There was no significant difference in the prevalence of fatty liver with ALT elevation in females with MS
between light drinkers and non-drinkers, suggesting that other factors such as BMI, WC, V-type MS, and lifestyle-related
disease may be more important than LAC for the prevalence of fatty liver with ALT elevation.
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The prevalence of MS defined as obese individuals with
abnormalities in hypertension, glucose metabolism, and
dyslipidemia, has been increasing in countries of both
advanced and emerging economies. This increase in
prevalence is problematic due to the association of MS
and various other diseases, as well as an increase med-
ical expenses. Additionally, in Asian and western coun-
tries, the prevalence of non-alcoholic fatty liver disease
(NAFLD), which is strongly associated with MS, has also
been increasing [1, 2]. Although heavy drinking is be-
lieved to lead to liver injury [3], several recent studies
have reported that moderate or light drinking plays a
protective role against fatty liver [4–8]. Drinking may be
problematic for persons with MS due to the differences
in clinical background between persons with and with-
out MS and the increase in total caloric intake due to
drinking. Although light alcohol consumption (LAC)
was shown to play a protective role against NAFLD in
males with MS in a recent study [9], the prevalence of
MS and NAFLD, and the influence of alcohol consump-
tion are known to differ markedly between males and fe-
males. The present study investigated the association
between LAC and fatty liver with alanine aminotransfer-
ase (ALT) elevation in females with MS.
Methods
Subjects and study design
Subjects were 20,853 females (mean age ± standard devi-
ation 49.2 ± 11.5 years range 17–88), residing around Ta-
kamatsu city, who underwent a regular health check-up
at our hospital between April 2008 and March 2012. We
excluded subjects who did not fulfill the diagnostic cri-
teria for MS, who were positive for hepatitis B surface
antigen (HBsAg) and/or hepatitis C antibody (HCVAb),
who did not hope to undergo ultrasound examination,
or who consumed 20 g/day or more of alcohol. All sub-
jects were informed that their clinical data may be retro-
spectively analyzed for an epidemiological study, and
informed consent was obtained. This study was a cross-
sectional study elucidating the association between LAC
and fatty liver with ALT elevation in females with MS.
The study design was approved by the Ethics Commit-
tees of Kagawa Prefectural Cancer Detection Center, and
the study was performed in conformity with the Declar-
ation of Helsinki.
Physical examination and serum biochemistry
Height and body weight were obtained from the partici-
pants. Height was measured to the nearest 0.1 cm and
body weight was measured to the nearest 0.1 kg. Body
mass index (BMI) was calculated as the weight (in kilo-
grams) divided by the square of the height (in meters).
Waist circumference (WC) was measured at the umbilicallevel. Venous blood samples were taken from all subjects
following a 12-h overnight fast. Aspartate aminotransfer-
ase (AST), ALT, gamma-glutamyl transpeptidase (GGT),
total cholesterol (T-CHO), high-density lipoprotein (HDL)
cholesterol, triglycerides (TG), low-density lipoprotein
(LDL) cholesterol, uric acid (UA), fasting plasma glucose
(FPG), and hemoglobin A1c (HbA1c) (National Glycohe-
moglobin Standardization Program [NGSP]) were ana-
lyzed immediately by common enzymatic methods using
an auto analyzer (TBA-80FR; Toshiba Medical System
Tokyo, Japan).
Evaluation of alcohol consumption
Lifestyle-related information such as medical history,
smoking status, and alcohol consumption were obtained
by a common standardized self-response questionnaire.
The amount of alcohol consumed per drinking day was
calculated in grams using representative percent alcohol
by volume for each type of alcoholic beverages: 5 % for
beer, 10 % for wine, 16 % for Japanese sake, 25 % for
shochu, and 34 % for whiskey. Subjects were divided into
two categories by the drinking information: non-
drinkers, those drinking 12 drinks (one drink means less
10 g) or less per year of less than one drink/drinking
day; and light drinkers those drinking, from more than
zero to less than 20 g/drinking day. In addition, light
drinkers were divided into two subcategories: minimal
drinkers, those drinking from more than zero to less
than 10 g/drinking day; and very light drinkers, those
drinking from 10 g to less than 20 g/drinking day.
Diagnosis of MS
There are several diagnostic criteria for MS. We used the
diagnostic criteria for MS proposed by the International
Diabetes Federation (IDF) because this criteria has been
used worldwide [10]. The MS criteria used in this study
were as follows: WC must exceed 80 cm, and two or more
of the following components must be present: (1) hyper-
tension: blood pressure ≥130/85 mmHg or medicated for
hypertension (2) dyslipidemia: HDL-C <50 mg/dl and/or
TG ≥150 mg/dl, or medicated for dyslipidemia (3) im-
paired glucose tolerance: FPG ≥100 mg/dl or medicated
for diabetes.
Ultrasonography
Standard ultrasonography was performed with the sub-
jects to assess the abdomen including the liver, gallbladder,
pancreas, kidney, and spleen, in a morning fasting state by
trained technicians. A Xario SSA-660A instrument was
used with a 3.5 MHz convex-array probe (Toshiba Med-
ical System, Tokyo, Japan) for ultrasonography. During
ultrasound examination, more than 20 abdominal images
were saved in the database and reviewed by gastroenterol-
ogists, who had more than 10 years of experience in
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Fig. 1 Flow diagram of subjects included and excluded from the
present study. MS =metabolic syndrome
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subject’s data, such as blood-test screening. We defined
fatty liver by ultrasonography by the presence of liver-
kidney echo contrast and liver brightness, as well as hav-
ing deep attenuation and/or liver vessel blurring [11]. A
liver biopsy is known to be the gold standard for the diag-
nosis of NAFLD. However, liver biopsy is not realistic to
perform in a medical check-up because this method has a
risk of bleeding. Thus, we investigated fatty liver with ALT
elevation in the present study. Alanine aminotransferase
elevation was defined as an ALT level of ≥31 IU/l in this
study. Also, visceral fat was assessed by the abdominal
wall fat index (AFI), defined by the ratio of preperitoneal
and subcutaneous fat thicknesses [12]. This procedure has
been widely employed in medical check-ups for the as-
sessment of visceral fat due to the significant correlation
between the ratio of visceral and subcutaneous fat area by
computed tomography (CT) and AFI by ultrasonography
[12]. Although CT is the best method for assessment of
the visceral fat, radiation exposure by CT is a risk for
young females. Therefore, we selected the use of ultrason-
ography to assess visceral fat in the present study.
Statistical analysis
This study was a cross-sectional study investigating the
association between LAC and fatty liver with ALT eleva-
tion in females with MS. Baseline data are expressed as
means ± standard deviation (SD) for all continuous vari-
ables and as subject number (%) for categorical variables.
All statistical differences were considered significant at a
P value of less than 0.05. The χ2-test or Student’s t-test
was used to compare and determine differences between
two groups for independent samples and the P value
was adjusted for confounding variables using analysis of
covariance. Factors with a significant influence on the
prevalence of fatty liver with ALT elevation were then
determined by univariate analysis. Age, BMI, WC, SBP,
DBP, TG, HDL-C, UA, IGT, MS type, smoking status,
and drinking status were then subjected to a multivariate
logistic regression analysis. Results are presented as odds
ratios (ORs) with 95 % confidence interval (CI) for each
variable. All statistical analyses were performed using
Med Calc Software (Broekstraat, Mariakerke, Belgium).
Results
Enrollment
Enrolled subjects are shown in Fig. 1. Initial participants
were 20,853 females who underwent a regular health
check-up between April 2008 and March 2012 at our hos-
pital. Subjects were enrolled after application of the inclu-
sion and exclusion criteria described in the Methods
section (Subjects and study design). Of the 20,853 subjects,
2606 (12.5 %) females fulfilled the diagnostic criteria for
MS. Of the 2606 subjects, 1306 subjects answered the self-response questionnaire, underwent physical examinations,
blood-test screening, and abdominal ultrasonography. Of
the 1306 subjects, we excluded 165 subjects who fulfilled
the exclusion criteria, and the remaining 1141 subjects were
enrolled in this study.
Subject characteristics
The characteristics of enrolled subjects are shown in
Table 1. Mean age BMI, and WC was 56.6 ± 8.3 years
(range, 29–85), 26.3 ± 3.6 kg/m2 (range, 18.5–50.8), and
90.0 ± 7.2 cm (range, 80–117.5), respectively. Prevalence
of hypertension, dyslipidemia, and impaired glucose tol-
erance (IGT) was 82.1, 93.4, and 74.7 %, respectively.
The prevalence of fatty liver in all subjects was 56.3 %.
Of the 1141 subjects with MS, the number of subjects
with visceral type MS (V-type MS) and subcutaneous
type MS (S-type MS) was 170 (14.9 %) and 971 (85.1 %),
respectively. The proportion of light drinkers was 30.1 %
in all subjects.
Clinical characteristics in light drinkers and non-drinkers
The comparison of clinical characteristics in females
with MS between light drinkers and non-drinkers is
shown in Table 2. The Pa value was adjusted for con-
founding variables including age, BMI, WC, smoking
history, dyslipidemia, hypertension, and IGT. Age, BMI,
and WC were significantly lower in light drinkers than
in non-drinkers. There was no significant difference in
the prevalence of hypertension, dyslipidemia, and IGT
between light drinkers and non-drinkers. HbA1c were
significantly lower in light drinkers than in non-drinkers.
Regarding liver enzyme, there was no significant differ-
ence in ALT or AST between light drinkers and non-
drinkers. In addition, there was no significant difference
in the prevalence of fatty liver or fatty liver with ALT
elevation between light drinkers and non-drinkers.
Table 1 Subject characteristics
Number 1141
Age (years) 56.6 ± 8.3
BMI (kg/m2) 26.3 ± 3.6
WC (cm) 90.0 ± 7.2
SBP (mmHg) 131.1 ± 14.1
DBP (mmHg) 78.0 ± 9.4
Hypertension, n (%) 937 (82.1 %)
T-CHO (mg/dl) 212.2 ± 33.3
TG (mg/dl) 122.5 ± 62.8
HDL (mg/dl) 59.8 ± 13.8
LDL (mg/dl) 135.9 ± 30.1
Dyslipidemia, n (%) 1066 (93.4 %)
UA (mg/dl) 4.9 ± 1.1
FPG (mg/dl) 107.9 ± 19.0
HbA1c (NGSP) (%) 6.0 ± 0.7
IGT, n (%) 852 (74.7 %)
ALT (IU/l) 27.2 ± 19.4
AST (IU/l) 23.7 ± 10.8
GGT (IU/l) 34.1 ± 31.2
FIB-4 index 2.7 ± 0.7
Fatty liver, n (%) 642 (56.3 %)
V-type MS, n (%) 170 (14.9 %)
Light drinker, n (%) 344 (30.1 %)
Past history of smoking, n (%) 103 (9.0 %)
Data are given as means ± standard deviation (SD), and as number (%) for
categorical variables
ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass
index, DBP diastolic blood pressure, FPG fasting plasma glucose, GGT
gamma-glutamyl transpeptidase, HbA1c hemoglobin A1c, HDL high density
lipoprotein, IGT impaired glucose tolerance, LDL low density lipoprotein, MS
metabolic syndrome, NGSP National Glycohemoglobin Standardization Program,
SBP systolic blood pressure, T- CHO total cholesterol, TG triglyceride, UA uric acid,
V-type visceral type, WC waist circumference. Light drinkers were subjects who
drank from more than zero to less than 20 g/day of alcohol
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drinkers
The comparison of clinical characteristics in females
with MS between minimal drinkers and very light
drinkers is shown in Table 3. The Pa value was ad-
justed for confounding variables including age, BMI,
WC, smoking history, dyslipidemia, hypertension, and
IGT. There was no significant difference in age, BMI,
and WC between minimal drinkers and very light
drinkers. SBP, DBP, and the prevalence of hypertension
were significantly lower in minimal drinkers than in
very light drinkers. HDL was significantly higher in
very light drinkers than in minimal drinkers. HbA1c
was significantly lower in very light drinkers than in
minimal drinkers. The prevalence of fatty liver and
ALT was significantly lower in very light drinkers than
in minimal drinkers.Treatment for lifestyle-related diseases in light drinkers
and non-drinkers
The comparison of those receiving treatment for lifestyle-
related diseases between light drinkers and non-drinkers
in females with MS is shown in Table 4. The Pa value was
adjusted for confounding variables including age, BMI,
WC, smoking history, dyslipidemia, hypertension, and
IGT. There was no significant difference in the prevalence
of those receiving treatment for hypertension, SBP, or
DBP between light drinkers and non-drinkers. The preva-
lence of those receiving treatment for dyslipidemia was
significantly lower in light drinkers than in non-drinkers.
The prevalence of those receiving treatment for IGT or
FBS in those receiving treatment for IGT was significantly
lower in light drinkers than in non-drinkers.
Predictors of fatty liver with ALT elevation
Univariate and multivariate independent predictors of fatty
liver with ALT elevation in females with MS are shown in
Table 5. Of the 20 items related to the clinical background
of subjects with or without fatty liver with ALT elevation,
14 items were identified as significant factors by univariate
analysis. Multiple logistic regression analysis was per-
formed with 12 items, with age, BMI, WC, SBP, DBP, TG,
HDL, UA, IGT, MS type, drinking status, and smoking sta-
tus as covariates. BMI, WC, DBP, TG, UA, IGT, and V-type
MS were significant and independent predictors of an in-
creased prevalence of fatty liver with ALT elevation. The
odds ratio [OR] (95 % confidence interval [CI], p value) for
fatty liver with ALT elevation were as follows: BMI, 2.181
(1.445–3.293, p <0.001); WC 1.853 (1.280–2.684, p <0.01);
DBP 1.604 (1.120–2.298, p <0.05); TG 2.202 (1.562–3.105,
p <0.001); UA 2.959 (1.537–5.698, p <0.01); IGT 1.692
(1.143–2.506, p <0.01); and V-type MS 3.708 (2.529–5.437,
p <0.001).
Discussion
This cross-sectional study explored the association be-
tween LAC and fatty liver with ALT elevation in females
with MS. The association between MS and NAFLD has
been shown to be mutually very strong [13, 14], and
NAFLD is thought to be a manifestation of MS in the
liver [13, 15, 16]. Light or moderate drinking has been
reported to play a protective role against fatty liver in
several studies [4–8]. Moreover, a recent study showed
that the prevalence of NAFLD was significantly lower in
light drinkers than in non-drinkers, and LAC was one of
the significant factors of decreased prevalence of
NAFLD, including males with MS [9]. However, the
prevalence of MS, NAFLD including fatty liver, and the
influence of alcohol consumption has been known to
differ markedly between males and females. Additionally,
females have been known to be more sensitive to the
hepatic effects of alcohol than males in clinical and
Table 2 Comparison of clinical characteristics in females with MS between light drinkers and non-drinkers
Light drinkers (n = 344) Non-drinkers (n = 797) P-value (Pa-value)
Age (years) 54.6 ± 7.9 57.5 ± 8.3 <0.001
BMI (kg/m2) 25.9 ± 3.5 26.4 ± 3.6 <0.05
WC (cm) 89.1 ± 7.1 90.3 ± 7.2 <0.05
SBP (mmHg) 129.7 ± 13.3 131.7 ± 14.4 (NS)
DBP (mmHg) 77.9 ± 9.3 78.0 ± 9.4 (NS)
Hypertension, n (%) 282 (82.0 %) 655 (82.2 %) (NS)
T-CHO (mg/dl) 214.6 ± 34.8 211.1 ± 32.6 (NS)
TG (mg/dl) 121.5 ± 64.8 122.9 ± 62.0 (NS)
HDL (mg/dl) 60.2 ± 13.8 59.7 ± 13.8 (NS)
LDL (mg/dl) 138.0 ± 31.1 135.0 ± 29.6 (NS)
Dyslipidemia, n (%) 324 (99.4 %) 742 (93.1 %) (NS)
UA (mg/dl) 4.9 ± 1.1 4.9 ± 1.1 (NS)
FPG (mg/dl) 106.5 ± 14.4 108.5 ± 20.6 (NS)
HbA1c (NGSP) (%) 5.9 ± 0.6 6.1 ± 0.8 (<0.05)
IGT, n (%) 261 (75.9 %) 591 (74.2 %) (NS)
ALT (IU/l) 27.2 ± 21.4 27.2 ± 18.5 (NS)
AST (IU/l) 23.0 ± 9.9 24.0 ± 11.2 (NS)
GGT (IU/l) 32.3 ± 27.4 34.8 ± 32.6 (NS)
FIB-4 index 2.5 ± 0.6 2.7 ± 0.7 (NS)
Fatty liver, n (%) 188 (54.7 %) 454 (57.0 %) (NS)
FL with ALT elevation, n (%) 76 (22.1 %) 177 (22.2 %) (NS)
V-type MS, n (%) 55 (16.0 %) 115 (14.4 %) (NS)
Past history of smoking, n (%) 49 (14.2 %) 54 (6.8 %) <0.001
Data are given as means ± standard deviation (SD), and as number (%) for categorical variables. P-value is based on the X2 test or Student’s t-test. Significant is at
the 5 % level
ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, DBP diastolic blood pressure, FL fatty liver, FPG fasting plasma glucose, GGT
gamma-glutamyl transpeptidase, HbA1c hemoglobin A1c, HDL high density lipoprotein, IGT impaired glucose tolerance, LDL low density lipoprotein, MS metabolic
syndrome, NGSP National Glycohemoglobin Standardization Program, NS not significant, SBP systolic blood pressure, T- CHO total cholesterol, TG triglyceride, UA
uric acid, V-type visceral type, WC waist circumference. ALT elevation was defined as ALT level of >31 IU/l in this study. Light drinkers were subjects who drank
from more than zero to less than 20 g/day of alcohol. Non-drinkers were subjects who drank 12 drinks (one drink means less 10 g) or less per year of less than
10 g/drinking day
aAdjusted for age, BMI, WC, smoking history, dyslipidemia, hypertension, and IGT
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between LAC and fatty liver with ALT elevation in fe-
males with MS is unclear. Results from this study dem-
onstrated that there was no significant difference in the
prevalence of fatty liver with ALT elevation between
light drinkers and non-drinkers; however, the preva-
lence of those undergoing treatment for dyslipidemia
and IGT was significantly lower in light drinkers than
in non-drinkers in females with MS. BMI, WC, V-type
MS, and lifestyle-related disease were important factors
for the prevalence of fatty liver with ALT elevation in
females with MS.
Ethanol induces hepatic lipid synthesis and may re-
duce hepatic fatty acid oxidation [20]. However alcohol
consumption is known to cause fatty liver in some cases
[20, 21]. Light or moderate drinking was associated with
a lower incidence of hypertransaminasemia [5, 6] and adecreased risk of fatty liver [4, 7, 8] in recent clinical
studies. The prevalence of fatty liver was reported to be
significantly decreased by light or moderate drinking in
a study with asymptomatic Japanese male subjects [7].
However, the influence of alcohol intake is known to dif-
fer between males and females [17–19, 22], and the as-
sociation between liver enzyme, NAFLD including fatty
liver, and LAC in females has been controversial. It was
reported that the odds ratio for MS was decreased to
less than 1 in females with LAC [23], and the prevalence
of fatty liver in females was reported to be significantly
lower in drinkers than in non-drinkers [8]. On the other
hand, it was reported in a recent study that there was no
association between the prevalence of elevated liver en-
zyme levels and alcohol consumption in females [24].
Additionally, in a recent prospective study from the UK,
excess body weight was reported to contribute to almost
Table 3 Comparison of clinical characteristics in females with MS between minimal drinkers and very light drinkers
Minimal drinkers (n = 250) Very light drinkers (n = 94) P-value (Pa-value)
Age (years) 54.6 ± 7.9 54.5 ± 7.8 NS
BMI (kg/m2) 25.8 ± 3.3 26.0 ± 4.0 NS
WC (cm) 89.0 ± 6.8 89.5 ± 8.0 NS
SBP (mmHg) 128.9 ± 13.4 131.8 ± 12.8 (<0.01)
DBP (mmHg) 77.3 ± 9.9 79.6 ± 7.5 (<0.01)
Hypertension, n (%) 197 (78.8 %) 85 (90.4 %) (<0.001)
T-CHO (mg/dl) 213.2 ± 34.8 218.5 ± 34.5 (NS)
TG (mg/dl) 123.3 ± 67.7 116.6 ± 56.3 (NS)
HDL (mg/dl) 59.3 ± 13.9 62.8 ± 13.2 (<0.05)
LDL (mg/dl) 137.1 ± 31.0 140.3 ± 31.5 (NS)
Dyslipidemia, n (%) 235 (94.0 %) 89 (94.7 %) (NS)
UA (mg/dl) 4.9 ± 1.1 5.1 ± 1.1 (NS)
FPG (mg/dl) 106.7 ± 14.7 105.9 ± 13.6 (NS)
HbA1c (NGSP) (%) 6.0 ± 0.6 5.8 ± 0.4 (<0.05)
IGT, n (%) 186 (74.4 %) 75 (79.8 %) (NS)
ALT (IU/l) 28.5 ± 23.2 23.9 ± 15.2 (<0.05)
AST (IU/l) 23.0 ± 10.4 22.0 ± 8.0 (NS)
GGT (IU/l) 30.5 ± 22.9 36.9 ± 36.6 (NS)
FIB-4 index 2.5 ± 0.6 2.5 ± 0.6 (NS)
Fatty liver, n (%) 148 (59.2 %) 40 (42.6 %) (<0.01)
FL with ALT elevation, n (%) 60 (24.0 %) 16 (17.0 %) (NS)
V-type MS, n (%) 39 (15.6 %) 16 (17.0 %) (NS)
Past history of smoking, n (%) 28 (11.2 %) 21 (22.3 %) <0.05
Data are given as means ± standard deviation (SD), and as number (%) for categorical variables. P-value is based on the X2 test or Student’s t-test. Significant is at
the 5 % level
ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, DBP diastolic blood pressure, FL fatty liver, FPG fasting plasma glucose, GGT
gamma-glutamyl transpeptidase, HbA1c hemoglobin A1c, HDL high density lipoprotein, IGT impaired glucose tolerance, LDL low density lipoprotein, MS metabolic
syndrome, NGSP National Glycohemoglobin Standardization Program, NS not significant, SBP systolic blood pressure, T- CHO total cholesterol, TG triglyceride, UA
uric acid, V-type visceral type, WC waist circumference. ALT elevation was defined as ALT level of >31 IU/l in this study. Minimal drinkers were subjects who drank
from more than zero to less than 10 g/day of alcohol. Very light drinkers were subjects who drank from 10 to less than 20 g/day of alcohol
aAdjusted for age, BMI, WC, smoking history, dyslipidemia, hypertension, and IGT
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deaths in middle-aged female subjects, and alcohol con-
sumption contributed to almost 50 % [25]. However, in
the majority of reports on the effect of alcohol consump-
tion on MS, subjects were almost always from a general
population and were not divided into those with and
without MS, or those with fatty liver were not divided
with respect to liver enzyme elevation. To address this,
the present study was limited to only female subjects
with MS, and showed that there was no significant dif-
ference in the prevalence of fatty liver with ALT eleva-
tion between light drinkers and non-drinkers.
The mechanism of this inverse association between
drinking and NAFLD including fatty liver remains un-
clear. Light to moderate drinking may enhance insulin
sensitivity [21, 26] and reduce the risk of non-alcoholic
steatohepatitis, possibly due to reduced insulin resist-
ance [4]. Although the present study showed that therewas no significant difference in the prevalence of fatty
liver with ALT elevation or IGT between light drinkers
and non-drinkers, the prevalence of those undergoing
treatment for IGT was significantly lower in light
drinkers than in non-drinkers in females with MS. It is
known that obesity increases fat deposition in hepato-
cytes and the progression of fatty liver, which may lead
to inflammation, liver fibrosis, and liver cirrhosis [27].
The improvement of insulin sensitivity by light drinking
may have been weak because subjects in the present
study were obese with MS. The beneficial effects of re-
ducing a risk of fatty liver may be weak in light female
drinkers with MS, due to the lack of significant differ-
ence in insulin sensitivity between light drinkers and
non-drinkers in females with MS.
Although it was reported that drinking had a positive
effect on HDL-C levels [28], there was no significant dif-
ference in HDL levels between light drinkers and non-
Table 4 Comparison of those receiving treatment for lifestyle-related diseases between light drinkers and non-drinkers in females
with MS
Lifestyle-related disease Presence of treatment Light drinkers (n = 344) Non-drinkers (n = 797) P-value (Pa-value)
Hypertension Treatment (+), n (%) 128 (37.2 %) 330 (41.4 %) NS
SBP (mmHg) 130.5 ± 13.7 133.2 ± 15.7 (NS)
DBP (mmHg) 77.3 ± 8.6 78.6 ± 9.2 (NS)
Treatment (−), n (%) 216 (62.8 %) 467 (58.6 %)
SBP (mmHg) 129.2 ± 13.0 130.6 ± 13.4 (NS)
DBP (mmHg) 78.3 ± 9.7 77.6 ± 9.6 (NS)
Dyslipidemia Treatment (+), n (%) 85 (24.7 %) 320 (40.2 %) <0.01
T-CHO (mg/dl) 197.8 ± 32.4 201.0 ± 26.5 (NS)
TG (mg/dl) 116.3 ± 49.4 113.4 ± 52.6 (NS)
HDL (mg/dl) 63.8 ± 13.8 63.0 ± 14.0 (NS)
LDL (mg/dl) 119.2 ± 26.3 122.7 ± 23.4 (NS)
Treatment (−), n (%) 259 (75.3 %) 477 (59.8 %)
T-CHO (mg/dl) 220.2 ± 33.8 218.0 ± 34.5 (NS)
TG (mg/dl) 123.2 ± 69.1 129.3 ± 66.9 (NS)
HDL (mg/dl) 59.1 ± 13.6 57.4 ± 13.1 (NS)
LDL (mg/dl) 144.2 ± 30.1 143.3 ± 30.5 (NS)
IGT Treatment (+), n (%) 17 (4.9 %) 72 (9.0 %) <0.05
FBS (mg/dl) 124.1 ± 25.4 138.1 ± 33.4 (<0.05)
HbA1c (NGSP) (%) 6.9 ± 0.9 7.2 ± 1.1 (NS)
Treatment (−), n (%) 327 (95.1 %) 725 (91.0 %)
FBS (mg/dl) 105.6 ± 13.0 105.5 ± 16.2 (NS)
HbA1c (NGSP) (%) 5.9 ± 0.5 6.0 ± 0.7 (NS)
Data are given as means ± standard deviation (SD), and as number (%) for categorical variables. P-value is based on the x2 test or Student’s t-test. Significant is at
the 5 % level
DBP diastolic blood pressure, FPG fasting plasma glucose, HbA1c hemoglobin A1c, HDL high density lipoprotein, IGT impaired glucose tolerance, LDL low density
lipoprotein, NGSP National Glycohemoglobin Standardization Program, NS not significant, SBP systolic blood pressure, T-CHO total cholesterol, TG triglyceride, Light
drinkers were subjects who drank from more than zero to less than 20 g/day of alcohol. Non-drinkers were subjects who drank 12 drinks (one drink means less
10 g) or less per year ofless than 10 g/drinking day
aAdjusted for age, BMI, WC, smoking history, dyslipidemia, hypertension, and IGT
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estingly, HDL was significantly higher in very light
drinkers than in minimal drinkers. The effect of alcohol
consumption on MS in the general population remains
controversial. Although several reports have shown that
the prevalence of MS is associated with alcohol con-
sumption, irrespective of the amount consumed [29, 30],
some another studies have reported beneficial effects of
alcohol consumption on MS [31, 32]. It was recently re-
ported that the prevalence of fatty liver was decreased
along with the level of alcohol consumption in males sub-
jects with MS, and alcohol consumption was associated
with higher blood pressure, higher fasting plasma glucose,
and a lower level of HDL-C in the male subjects who
drank from more than zero to an excess of 280 g/week
[23]. Although the present study showed that there was
no significant difference in the prevalence of fatty liver
with ALT elevation, hypertension, dyslipidemia, or IGT
between light drinkers and non-drinkers, the prevalenceof those undergoing treatment for dyslipidemia or IGT
was significantly higher in non-drinkers than light
drinkers. These results suggest that females may differ
from males in sensitivity to the hepatic effects of alcohol
due to some factors, such as pharmacokinetics or metab-
olism of alcohol [18]. Additionally, the present results may
also be influenced by the difference in adipose tissue dis-
tribution [33, 34], estrogen-related sex hormones [35, 36],
treatment for lifestyle-related disease, and other social life-
style factors, such as physical activity, exercise, diet, and
drinking patterns between males and females. Further in-
vestigation is warranted, due to the lack of more detailed
investigation on social lifestyle factors.
We do not suggest that drinking is recommended for
non-drinkers because LAC was not a significant factor
of a decreased prevalence of fatty liver with ALT eleva-
tion in the present study, and the effects of drinking dif-
fer among individuals. Increased drinking is also not
recommended for minimal drinkers. Although ALT and
Table 5 Results of univariate and multivariate: independent predictors of fatty liver with ALT elevation in females with MS
Univariate analysis Multivariate analysis
FL with ALT elevation (+) (n = 253) FL with ALT elevation (−) (n = 888) P-value OR 95 % CI P-value
Age (≧50/< 50 years) 187/66 739/149 <0.01 1.003 0.677–1.484 NS
BMI (≧25/< 25 kg/m2) 199/54 469/419 <0.001 2.181 1.445–3.293 <0.001
WC (≧90/< 90 cm) 166/87 348/540 <0.001 1.853 1.280–2.684 <0.01
SBP (≧130/< 130 mmHg) 138/115 557/331 <0.05 0.756 0.543–1.053 NS
DBP (≧85/< 85 mmHg) 76/177 197/691 <0.05 1.604 1.120–2.298 <0.05
Hypertension (+/−) 209/44 728/160 NS
T-CHO (≧220/< 220 mg/dl) 103/150 340/548 NS
TG (≧150/< 150 mg/dl) 105/148 206/682 <0.001 2.202 1.562–3.105 <0.001
HDL (<50/≧ 50 mg/dl) 96/157 217/671 <0.001 1.362 0.955–1.942 NS
LDL (≧140/< 140 mg/dl) 118/135 365/523 NS
Dyslipidemia (+/−) 236/17 58/830 NS
UA (≧7.0/< 7.0 mg/dl) 24/229 23/865 <0.001 2.959 1.537–5.698 <0.01
FPG (≧100/< 100 mg/dl) 202/51 641/247 <0.05
HbA1c (≧6.5/< 6.5 % NGSP) 70/183 110/778 <0.001
IGT (+/−) 204/49 648/240 <0.05 1.692 1.143–2.506 <0.01
AST (≧31/< 31 IU/l) 140/113 21/867 <0.001
GGT (≧51/< 51 IU/l) 90/163 94/794 <0.001
V-type MS/S-type MS 82/171 88/800 <0.001 3.708 2.529–5.437 <0.001
Light drinker/Non-drinker 76/177 268/620 NS 0.988 0.699–1.396 NS
Past history of smoking (+/−) 31/222 72/816 NS 1.182 0.705–1.981 NS
Significant is at the 5 % level
ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, CI confidence interval, DBP diastolic blood pressure, FL fatty liver, FPG fasting
plasma glucose, GGT gamma-glutamyl transpeptidase, HbA1c hemoglobin A1c, HDL high density lipoprotein, IGT impaired glucose tolerance, LDL low density
lipoprotein, MS metabolic syndrome, NGSP National Glycohemoglobin Standardization Program, NS not significant, OR odds ratio, SBP systolic blood pressure,
S-type subcutaneous-type, T-CHO total cholesterol, TG triglyceride, UA uric acid, V-type visceral type, WC waist circumference. Light drinkers were subjects who
drank from more than zero to less than 20 g/day of alcohol. Non-drinkers were subjects who drank 12 drinks (one drink means less 10 g) or less per year of less
than 10 g/drinking day. ALT elevation was defined as ALT level of >31 IU/l in this study
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very light drinkers than in minimal drinkers, the preva-
lence of hypertension was significantly higher in very
light drinkers than in minimal drinkers. Alanine amino-
transferase and lifestyle-related diseases, such as hyper-
tension, dyslipidemia, and IGT, may be more affected in
non-drinkers and minimal drinkers with MS by the in-
creased eating duration due to alcohol consumption.
Interestingly, the prevalence of hypertension in light
daily drinkers (from more than zero to less than 10 g/
every day) was shown to be significantly higher than in
non-drinkers in the present study (data not shown). In
addition, individuals with MS and patients with risk of
drinking abuse should not be advised to drink heavily. In
particular, heavy drinking should not be recommended
for individuals with MS because excess alcohol con-
sumption is known to be a risk for mortality and death
from noncardiovascular causes [37, 38], and MS is
known to be a risk factor for arteriosclerotic diseases
and ischemic heart disease [39]. Despite the possibility
that heavy drinking may have a beneficial effect againstfatty liver and on liver enzyme, we emphasize that heavy
drinking should not be recommended for individuals
with MS.
There are some limitations that should be noted in the
present study. First the present study did not investigate
the underlying mechanism between the association of
LAC and fatty liver with ALT elevation in females with
MS, due to the nature of the cross-sectional design. Sec-
ond, detailed data, such as contents of subjects’ diets,
eating duration, total caloric intake, and physical activity
were not investigated. Third, although the subjects in
the present study were females, the state of menses was
not investigated, and the levels of estrogen-related sex
hormones were not measured. Fourth, there was a possi-
bility that the proportion of those with mild steatosis un-
detectable by ultrasound may have been higher in light
drinking subjects than in non-drinkers, because the sen-
sitivity of detecting steatosis by ultrasound is known to
be below 20–30 %. Fifth, although ALT is known to be a
simple marker of liver enzymes, ALT is unable to reflect
the severity of NAFLD. Last, there was a possibility of
Sogabe et al. BMC Gastroenterology  (2016) 16:17 Page 9 of 10selection bias subjects in the present study may have
high interest in health because they hoped to undergo a
medical check-up in Ningen Dock. Further studies will
be required to resolve these limitations.
Conclusion
The present study showed that there was no significant
difference in the prevalence of fatty liver with ALT eleva-
tion between light drinkers and non-drinkers in females
with MS. Body mass index, WC, DBP, TG, UA, IGT, and
V-type MS were significant factors of an increased preva-
lence of fatty liver with ALT elevation, and the prevalence
of individuals undergoing treatment for dyslipidemia or
IGT was significantly lower in light drinkers than in non-
drinkers in females with MS. We believe that BMI, WC,
V-type MS, and lifestyle-related disease may be more im-
portant factors for the prevalence of fatty liver with ALT
elevation than LAC in Japanese females with MS.
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